Cleared Traditional

Xenta Drug Screen Cup, Xenta Drug Screen Dipcard (K222955) - FDA 510(k) Clearance

Class II Toxicology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K222955 · Xenta Biomedical Science Co., Ltd. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 2023
Decision
132d
Days
Class 2
Risk

K222955 is an FDA 510(k) clearance for the Xenta Drug Screen Cup, Xenta Drug Screen Dipcard. Classified as Enzyme Immunoassay, Opiates (product code DJG), Class II - Special Controls.

Submitted by Xenta Biomedical Science Co., Ltd. (Guangzhou, CN). The FDA issued a Cleared decision on February 6, 2023 after a review of 132 days - within the typical 510(k) review window.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3650 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Toxicology review framework, consistent with the majority of Class II 510(k) submissions.

View all Xenta Biomedical Science Co., Ltd. devices

Submission Details

510(k) Number K222955 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 27, 2022
Decision Date February 06, 2023
Days to Decision 132 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
45d slower than avg
Panel avg: 87d · This submission: 132d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DJG Enzyme Immunoassay, Opiates
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3650
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DJG Enzyme Immunoassay, Opiates

All 88
Devices cleared under the same product code (DJG) and FDA review panel - the closest regulatory comparables to K222955.
AllTest Fentanyl Rapid Test (Urine)
K231698 · Hangzhou AllTest Biotech Co., Ltd. · Jul 2023
Emit® II Plus Buprenorphine Assay
K221605 · Siemens Healthcare Diagnostics, Inc. · Jul 2023
BIOEASY™ U-Catch MAX Multi-Drug Test Cup, BIOEASY™ U-Catch MAX Multi-Drug Test Cup Rx
K230238 · Shenzhen Bioeasy Biotechnology Co., Ltd. · Mar 2023
Superbio Fentanyl Urine Detection Kit, Superbio Immunofluorescence Analyzer EASY-11
K220046 · Shenzhen Superbio Technology Co., Ltd. · Dec 2022
Immunalysis Tapentadol Urine HEIA
K203527 · Lmmunalysis Corporation · May 2022
SEFRIA Oxycodone Oral Fluid Enzyme Immunoassay
K203564 · Immunalysis Corporation · Dec 2021